Lenta 10mg Capsule

Lenta 10mg Capsule drug is a member of the antineoplastic class of cancer-fighting drugs as it contains active ingredient Lenvatinib (10mg). It is used to treat thyroid, kidney, and liver cancers, and Endometrial cancer.

It reduces the size of tumors in individuals with the disease by blocking particular proteins that encourage the growth and metastasis of cancer cells. This medication can be used with or without food. The precise dosage will be determined by your physician.

• Differentiated Thyroid cancer
• Treatment of Kidney cancer
• Liver cancer
• Treatment of Endometrial cancer

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Lenta 10mg Capsule include:

• High or low BP
• Loss of appetite
• Nausea, vomiting, constipation, diarrhea, or indigestion
• Tiredness
• Hoarse voice
• Leg swelling
• Rashes
• Pain in joints or muscles
• Hair loss
• Sleeplessness
• Protein in urine, frequent urination
• Low potassium, magnesium and calcium levels in the blood
• Dehydration
• Skin problems
• Gall bladder inflammation
• Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes
• Delayed wound healing

Contact your healthcare provider if you face any unusual or persistent side effects.   

• Take Lenta 10mg Capsule in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age, type & stage of the cancer, and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.​​
  

• Lenta 10mg Capsule contains Lenvatinib, which is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3.
• Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET.
• As a result, it slows the progression of cancer. After the oral administration, the effect of this medicine can be observed in 1 to 4 hours.​​
  

• Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., ... & Choueiri, T. K. (2021). Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine, 384(14), 1289-1300. https://pubmed.ncbi.nlm.nih.gov/33616314/
• Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., ... & Takahashi, S. (2017). Lenvatinib for anaplastic thyroid cancer. Frontiers in oncology, 7, 25. https://pubmed.ncbi.nlm.nih.gov/28299283/
• Makker, V., Colombo, N., Casado Herráez, A., Santin, A. D., Colomba, E., Miller, D. S., ... & Lorusso, D. (2022). Lenvatinib plus pembrolizumab for advanced endometrial cancer. New England Journal of Medicine, 386(5), 437-448. https://pubmed.ncbi.nlm.nih.gov/35045221/
• Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., ... & Sherman, S. I. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine, 372(7), 621-630. https://pubmed.ncbi.nlm.nih.gov/25671254/
• Suyama, K., & Iwase, H. (2018). Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer control, 25(1), 1073274818789361. https://pubmed.ncbi.nlm.nih.gov/30032643/
• Al-Salama, Z. T., Syed, Y. Y., & Scott, L. J. (2019). Lenvatinib: a review in hepatocellular carcinoma. Drugs, 79(6), 665-674.